ADAP - Adaptimmune Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Adaptimmune Therapeutics plc

60 Jubilee Avenue
Milton Park
Abingdon OX14 4RX
United Kingdom
44 12 3543 0000
http://www.adaptimmune.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees406

Key Executives

NameTitlePayExercisedYear Born
Mr. James Julian NobleCEO & Director814.55kN/A1959
Dr. Helen Katrina Tayton-MartinCo-Founder & Chief Bus. Officer549.52kN/A1967
Mr. Adrian RawcliffeChief Financial Officer678.6k1.03M1972
Mr. William C. Bertrand Jr.Chief Operating Officer608.52kN/A1965
Dr. Rafael AmadoPres of R&D710.14kN/A1964
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Corporate Governance

Adaptimmune Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.